CoDa raises NZ$25m to fund wound treatment
26 July, 2012 by Dylan Bushell-EmblingNZ biotech CoDa Therapeutics has received a NZ$24.5 million funding injection from a Russian investor, to help continue commercialisation of wound therapy Nexagon.
Mesoblast eyes human trials of stem cell treatment for rheumatoid arthritis
25 July, 2012 by Dylan Bushell-EmblingAnimal trials of Mesoblast's (ASX:MSB) mesenchymal stem cells in rheumatoid arthritis (RA) have encouraged the company press on with an FDA application for a phase II trial.
AtCor files FDA application for cardiovascular monitor
25 July, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has submitted an application for approval to market its updated SphygmoCor XCEL cardiovascular monitoring system in the US.
Positive results from C-Pulse follow-up
25 July, 2012 by Dylan Bushell-EmblingSunshine Heart (ASX:SHC) has released promising 12-month follow-up data from the feasibility trial for its C-Pulse Heart Assist System, as the trial heads into the two-year follow-up stage.
Bioniche canine cancer product approved in NA
25 July, 2012 by Dylan Bushell-EmblingUS and Canadian regulators have approved Immunocidin, the first of two canine cancer products developed by Bioniche (ASX:BNC).
AusIndustry to hold registration workshops on Tax Incentive
24 July, 2012 by AusBiotechAusIndustry is holding registration ready workshops to help companies better understand and register for the R&D Tax Incentive.
pSivida gets FDA nod for phase III Medidur trial
23 July, 2012 by Dylan Bushell-EmblingThe FDA has cleared pSivida (ASX:PVA) to jump straight to phase III trials of its micro-insert to deliver a posterior uveitis treatment, and to cite partner Alimera's data in its IND application.
Narhex ex-CEO licenses HIV treatment for Mexico
23 July, 2012 by Dylan Bushell-EmblingNarhex (ASX:NLS) founder and former CEO John Majewski will form a new company to register and commercialise a HIV treatment developed under his watch in the Mexican market.
Feature: Banking on nature
23 July, 2012 by Graeme O'NeillThe Eskitis Institute’s Nature Bank holds a huge array of natural compounds for screening as potential drug leads, and researchers have invented a revolutionary new mass spectrometry tool to detect binding reactions with molecular targets.
Iluvien on the march in Europe
20 July, 2012 by Tim DeanpSivida (ASX:PVA) has had two wins this week for Iluvien, its treatment for vision impairment associated with chronic diabetic macular edema (DME).
BioDiem partners with RMIT to extend vaccine technology
20 July, 2012 by Tim DeanBioDiem (ASX:BDM) is looking to develop its vaccine technology to target indications beyond influenza through a research partnership with RMIT.
UQ-led teams to develop advanced cattle vaccines
19 July, 2012 by Dylan Bushell-EmblingTwo University of Queensland scientists are leading teams to develop cutting-edge vaccines aimed at fighting cattle tick infestation and common bovine diseases.
Top performing biotechs delivered over 100% returns in FY12
19 July, 2012 by Dylan Bushell-EmblingThe three top performing life science stocks over the last four quarters delivered more than 100% returns over that time.
Sirtex study to pave way for wider use of SIR-Spheres
19 July, 2012 by Dylan Bushell-EmblingA large-scale trial could pave the way for wider adoption of Sirtex Medical's (ASX:SRX) SIR-Spheres in first-line oncology therapy.
Commercialisation Australia to provide more support for manufacturing
19 July, 2012 by AusBiotechNew funding guidelines, foreshadowed in December, deliver more generous arrangements for early stage commercialisation (ESC) grant recipients needing to establish manufacturing facilities in Australia to fully commercialise their invention.
